SA PRO
Free Account
ARS Pharmaceuticals, Inc.SPRYNASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 40% recommend buying.

Consensus Rating
Buy
10 analysts·Moderate coverage
40%
Rating Distribution
Strong Buy
110%
Buy
330%
Hold
660%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Nov 4, 2025Roth Capital
ARS Pharmaceuticals resumed with a Buy at Roth Capital
Target:$30.00
+256.5%from $8.41
Sep 26, 2025Raymond James
Raymond James positive on ARS Pharmaceuticals after weekly data
Target:$32.00
+230.4%from $9.69
Aug 19, 2024Cantor Fitzgerald
ARS Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
Target:$30.00
+110.7%from $14.24
Aug 12, 2024Raymond James
ARS Pharmaceuticals upgraded to Strong Buy from Outperform at Raymond James
Target:$22.00
+102.8%from $10.85
Jul 25, 2024Raymond James
ARS Pharmaceuticals initiated with an Outperform at Raymond James
Target:$18.00
+73.1%from $10.40
Mar 5, 2024Leerink Partners
Leerink Partners Upgrades ARS Pharmaceuticals Inc (SPRY) to Outperform
Target:$18.00
+108.1%from $8.65
Dec 13, 2022Leerink Partners
SVB Leerink Initiates Coverage On ARS Pharmaceuticals with Outperform Rating, Announces Price Target of $14
Target:$14.00
+96.6%from $7.12

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance